nach oben

Erschienen in:

19.11.2018 | Original Research Article

Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes

verfasst von: Mayara Rodrigues Brandão De Paiva, Nayara Almeida Lage, Maria Carolina Andrade Guerra, Marcos Paulo Gomes Mol, Marcela Coelho Silva Ribeiro, Gustavo De Oliveira Fulgêncio, Dawidson A. Gomes, Isabela Da Costa César, Sílvia Ligório Fialho, Armando Silva-Cunha

Erschienen in: Documenta Ophthalmologica | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the in vivo release profile and the retinal toxicity of a poly (lactic-co-glycolic acid) (PLGA) sustained-release sirolimus (SRL) intravitreal implant in normal rabbit eyes.

Methods

PLGA intravitreal implants containing or not SRL were prepared, and the viability of ARPE-19 and hES-RPE human retinal cell lines was examined after 24 and 72 h of exposure to implants. New Zealand rabbits were randomly divided into two groups that received intravitreal implants containing or not SRL. At each time point (1–8 weeks), four animals from the SRL group were euthanized, the vitreous was collected, and drug concentration was calculated. Clinical evaluation of the eyes was performed weekly for 8 weeks after administration. Electroretinography (ERG) was recorded in other eight animals, four for each group, at baseline and at 24 h, 1, 4, 6, and 8 weeks after the injection. ERG was carried out using scotopic and photopic protocols. The safety of the implants was assessed using statistical analysis of the ERG parameters (a and b waves, a and b implicit time, B/A ratio, oscillatory potential, and Naka–Rushton analysis) comparing the functional integrity of the retina between the PLGA and SRL-PLGA groups. After the last electrophysiological assessment, the rabbits were euthanized and retinal histopathology was realized.

Results

After 24 and 72 h of incubation with PLGA or SRL-PLGA implants, ARPE-19 and hES-RPE cells showed viability over 70%. The maximum concentration of SRL (199.8 ng/mL) released from the device occurred within 4 weeks. No toxic effects of the implants or increase in the intraocular pressure was observed through clinical evaluation of the eye. ERG responses showed no significant difference between the eyes that received PLGA or SRL-PLGA implants at baseline and throughout the 8 weeks of follow-up. No remarkable difference in retinal histopathology was detected in rabbit eyes treated with PLGA or SRL-PLGA implants.

Conclusions

Intravitreal PLGA or SRL-PLGA implants caused no significant reduction in cell viability and showed no evident toxic effect on the function or structure of the retina of the animals. SRL was released from PLGA implant after application in the vitreous of rabbits during 8 weeks.

Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14:303–308CrossRefPubMed

Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80:844–848. https://doi.org/10.1136/bjo.80.9.844 CrossRefPubMedPubMedCentral

Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study. Ophthalmology 111:491–500. https://doi.org/10.1016/j.ophtha.2003.06.014 CrossRefPubMed

London NJS, Rathinam SR, Cunningham ET (2010) The epidemiology of uveitis in developing countries. Int Ophthalmol Clin 50:1–17. https://doi.org/10.1097/IIO.0b013e3181d2cc6b CrossRefPubMed

Hwang DK, Chou YJ, Pu CY, Chou P (2012) Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology 119:2371–2376. https://doi.org/10.1016/j.ophtha.2012.05.026 CrossRefPubMed

Tomkins-Netzer O, Talat L, Bar A et al (2014) Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 121:2387–2392. https://doi.org/10.1016/j.ophtha.2014.07.007 CrossRefPubMed

Chu DS, Johnson SJ, Mallya UG et al (2013) Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect 3:64. https://doi.org/10.1186/1869-5760-3-64 CrossRefPubMedPubMedCentral

Castiblanco C, Foster CS (2014) Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther 3:17–36. https://doi.org/10.1007/s40123-014-0023-x CrossRefPubMedPubMedCentral

Mérida S, Palacios E, Navea A, Bosch-Morell F (2015) New immunosuppressive therapies in uveitis treatment. Int J Mol Sci 16:18778–18795. https://doi.org/10.3390/ijms160818778 CrossRefPubMedPubMedCentral

10.

Kanda T, Shibata M, Taguchi M et al (2014) Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol 98:932–936. https://doi.org/10.1136/bjophthalmol-2013-304416 CrossRefPubMed

11.

Wong GK, Griffith S, Kojima I, Demain AL (1998) Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. J Antibiot 51(5):487–491. https://doi.org/10.7164/antibiotics.51.487 CrossRef

12.

Guba M (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMed

13.

Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964–972. http://www.molvis.org/molvis/v10/a115/

14.

Stahl A, Paschek L, Martin G et al (2008) Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 582:3097–3102. https://doi.org/10.1016/j.febslet.2008.08.005 CrossRefPubMed

15.

Abdur Rouf M, Vural I, Bilensoy E et al (2011) Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate. J Incl Phenom Macrocycl Chem 70:167–175. https://doi.org/10.1007/s10847-010-9885-2 CrossRef

16.

Terada N, Lucas JJ, Szepesi A et al (1993) Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 154:7–15. https://doi.org/10.1002/jcp.1041540103 CrossRefPubMed

17.

Napoli KL, Taylor PJ (2001) From beach to bedside: history of the development of sirolimus. Ther Drug Monit 23:559–586. https://doi.org/10.1097/00007691-200110000-00012 CrossRefPubMed

18.

Cholkar K, Gunda S, Earla R et al (2014) Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 16:610–622. https://doi.org/10.1208/s12249-014-0244-2 CrossRefPubMedPubMedCentral

19.

Simamora P, Alvarez JM, Yalkowsky SH (2001) Solubilization of rapamycin. Int J Pharm 213:25–29. https://doi.org/10.1016/S0378-5173(00)00617-7 CrossRefPubMed

20.

MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22(Suppl B):B101–B121. https://doi.org/10.1016/s0149-2918(00)89027-x CrossRefPubMed

21.

Roberge FG, Xu D, Chan CC et al (1993) Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 12:197–203. https://doi.org/10.3109/02713689308999487 CrossRefPubMed

22.

Shanmuganathan VA (2005) The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 89:666–669. https://doi.org/10.1136/bjo.2004.048199 CrossRefPubMedPubMedCentral

23.

Ibrahim MA, Sepah YJ, Watters A et al (2015) One-year outcomes of the save study: sirolimus as a therapeutic approach for uveitis. Transl Vis Sci Technol 4:4. https://doi.org/10.1167/tvst.4.2.4 CrossRefPubMedPubMedCentral

24.

Perry I, Neuberger J (2005) Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 139:2–10. https://doi.org/10.1111/j.1365-2249.2005.02662.x CrossRefPubMedPubMedCentral

25.

Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Investig Ophthalmol Vis Sci 47:3339–3344. https://doi.org/10.1167/iovs.05-1425 CrossRef

26.

Douglas LC, Yi NY, Davis JL et al (2008) Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther 31:511–516. https://doi.org/10.1111/j.1365-2885.2008.00986.x CrossRefPubMed

27.

Hou H, Nieto A, Belghith A et al (2015) A sustained intravitreal drug delivery system with remote real time monitoring capability. Acta Biomater 24:309–321. https://doi.org/10.1016/j.actbio.2015.06.012 CrossRefPubMedPubMedCentral

28.

Mudumba S, Bezwada P, Takanaga H et al (2012) Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther 28:507–514. https://doi.org/10.1089/jop.2011.0226 CrossRefPubMed

29.

Nguyen QD, Ibrahim MA, Watters A et al (2013) Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 3:32. https://doi.org/10.1186/1869-5760-3-32 CrossRefPubMedPubMedCentral

30.

Nguyen QD, Merrill PT, Clark WL et al (2016) Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus study Assessing double-masKed Uveitis tReAtment (SAKURA). Ophthalmology 123:2413–2423. https://doi.org/10.1016/j.ophtha.2016.07.029 CrossRefPubMed

31.

Airody A, Heath G, Lightman S, Gale R (2016) Non-infectious uveitis: optimising the therapeutic response. Drugs 76:27–39. https://doi.org/10.1007/s40265-015-0502-y CrossRefPubMed

32.

Kuno N, Fujii S (2011) Recent advances in ocular drug delivery systems. Polymers (Basel) 3:193–221. https://doi.org/10.3390/polym3010193 CrossRef

33.

Kang-Mieler JJ, Osswald CR, Mieler WF (2014) Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin Drug Deliv 11:1647–1660. https://doi.org/10.1517/17425247.2014.935338 CrossRefPubMed

34.

da Silva R, Fialho SL, Siqueira RC et al (2010) Implants as drug delivery devices for the treatment of eye diseases. Braz J Pharm Sci 46:585–595. https://doi.org/10.1590/S1984-82502010000300024 CrossRef

35.

Fialho SL, Rêgo MB, Siqueira RC et al (2006) Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res 31:525–534. https://doi.org/10.1080/02713680600719036 CrossRefPubMed

36.

Thomson JA, Itzkovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147. https://doi.org/10.1126/science.282.5391.1145 CrossRefPubMed

37.

Klimanskaya I, Hipp J, Rezai KA et al (2004) Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. Cloning Stem Cells 6:217–245. https://doi.org/10.1089/clo.2004.6.217 CrossRefPubMed

38.

Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155–169CrossRefPubMed

39.

Fialho SL, Siqueira RC, Jorge R, Silva-Cunha A (2007) Biodegradable implants for ocular delivery of anti-inflammatory drug. J Drug Deliv Sci Technol 17:93–97. https://doi.org/10.1016/S1773-2247(07)50013-4 CrossRef

40.

McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12. https://doi.org/10.1007/s10633-014-9473-7 CrossRefPubMed

41.

Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y (2009) Ocular drug delivery; impact of in vitro cell culture models. J Ophthalmic Vis Res 4:238–252PubMedPubMedCentral

42.

ISO 10993-5. (2009) Biological evaluation of medical devices—Part 5: tests for in vitro cytotoxicity

43.

Forrest ML, Won CY, Malick AW, Kwon GS (2006) In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. J Control Release 110:370–377. https://doi.org/10.1016/j.jconrel.2005.10.008 CrossRefPubMed

44.

Onyesom I, Lamprou DA, Sygellou L et al (2013) Sirolimus encapsulated liposomes for cancer therapy: physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers. Mol Pharm 10:4281–4293. https://doi.org/10.1021/mp400362v CrossRefPubMed

45.

Li G, Cao L, Zhou Z et al (2015) Rapamycin loaded magnetic Fe₃O₄/carboxymethylchitosan nanoparticles as tumor-targeted drug delivery system: synthesis and in vitro characterization. Colloids Surf B Biointerfaces 128:379–388. https://doi.org/10.1016/j.colsurfb.2015.02.035 CrossRefPubMed

46.

Wang J, Jiang A, Joshi M, Christoforidis J (2013) Drug delivery implants in the treatment of vitreous inflammation. Mediat Inflamm. https://doi.org/10.1155/2013/780634 CrossRef

47.

Souza MCM, Fialho SL, Souza PAF et al (2014) Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. Curr Eye Res 39:99–102. https://doi.org/10.3109/02713683.2013.819927 CrossRefPubMed

48.

Fernandes-Cunha GM, Gouvea DR, de Oliveira Fulgêncio G et al (2015) Development of a method to quantify clindamycin in vitreous humor of rabbits’ eyes by UPLC-MS/MS: application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation. J Pharm Biomed Anal 102:346–352. https://doi.org/10.1016/j.jpba.2014.08.023 CrossRefPubMed

49.

Fialho SL, Souza PAF, de Oliveira Fulgêncio G et al (2013) In vivo release and retinal safety of intravitreal implants of thalidomide in rabbit eyes and antiangiogenic effect on the chorioallantoic membrane. J Drug Target 21:837–845. https://doi.org/10.3109/1061186X.2013.829074 CrossRefPubMed

50.

Fialho SL, Rego MGB, Cardillo JA et al (2003) Implantes biodegradáveis destinados à administração intra-ocular. Arq Bras Oftalmol 66:891–896. https://doi.org/10.1590/S0004-27492003000700029 CrossRef

51.

Haller JA, Bandello F, Belfort R et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118:2453–2460. https://doi.org/10.1016/j.ophtha.2011.05.014 CrossRefPubMed

52.

Klamann A, Böttcher K, Ackermann P et al (2017) Intravitreal dexamethasone implant for the treatment of postoperative macular edema. Ophthalmologica 236:181–185. https://doi.org/10.1159/000448057 CrossRef

53.

Kivilcim M, Peyman GA, Kazi AA et al (2007) Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 23:57–62. https://doi.org/10.1089/jop.2006.0083 CrossRefPubMed

54.

Peters T, Kim S-W, Castro V et al (2017) Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats. Biomaterials. https://doi.org/10.1016/j.biomaterials.2017.02.006 CrossRefPubMed

55.

Damico FM, Scolari MR, Ioshimoto GL et al (2012) Vitreous pharmacokinetics and electroretinographic findings after intravitreal injection of acyclovir in rabbits. Clinics (Sao Paulo) 67:931–937. https://doi.org/10.6061/Clinics/2012(08)13 CrossRef

56.

Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. https://doi.org/10.1007/s10633-016-9553-y CrossRefPubMed

57.

Manzano RPDA, Peyman GA, Khan P et al (2009) Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol 72:18–22. https://doi.org/10.1590/S0004-27492009000100004 CrossRefPubMed

58.

Nieto A, Hou H, Moon SW et al (2015) Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin. Investig Ophthalmol Vis Sci 56:1070–1080. https://doi.org/10.1167/iovs.14-15997 CrossRef

Titel: Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes
verfasst von: Mayara Rodrigues Brandão De Paiva
Nayara Almeida Lage
Maria Carolina Andrade Guerra
Marcos Paulo Gomes Mol
Marcela Coelho Silva Ribeiro
Gustavo De Oliveira Fulgêncio
Dawidson A. Gomes
Isabela Da Costa César
Sílvia Ligório Fialho
Armando Silva-Cunha
Publikationsdatum: 19.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Documenta Ophthalmologica / Ausgabe 1/2019
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-018-9664-8

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Visual evoked cortical potential elicited by pseudoisochromatic stimulus

Sub-hyaloid and sub-internal limiting membrane macular hemorrhage after laser exposure at music festival: a case report

Comparison between broadband and monochromatic photopic negative response in full-field electroretinogram in controls and subjects with primary open-angle glaucoma

Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3)

Acknowledgement to scientific referees 2018

Flash visual evoked potentials (FVEP) in various stimulation conditions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde